Clinical trials: Chronic Obstructive Pulmonary Disease, completed
Chronic Disease, Lung Diseases, Obstructive
Home-based Exercise Training for COPD Patients (HOMEX-2)
The aim of this study is to assess the effectiveness of a home-based exercise training program in COPD patients who did not participate in an inpatient or outpatient rehabilitation program within the last 2 years.
- Conditions
- Chronic Disease, Lung Diseases, Obstructive, Respiratory Disease
- Trial name
- NCT03654092
- Testing
- Exercise
- Where
- Switzerland
- Volunteers
- 50 people
- Sponsor
- University of Zurich
Chronic Obstructive Pulmonary Disease
Quantitative Study on HRCT Phenotype of COPD
To explore the HRCT phenotype of the combined COPD assessment staging system
- Trial name
- NCT04953611
- Where
- China
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Peking University Third Hospital
COPD (With - Without Rehabilitation), Diffuse Interstitial Lung Diseases
Development of a New Tool for Dyspnea Measurement in Chronic Respiratory Diseases
The purpose of this study is the psychometric validation of a self-administered dyspnea questionnaire, usable in clinical practice in order to assess dyspnea and its impact on patients with chronic respiratory diseases.
- Conditions
- COPD (With - Without Rehabilitation), Diffuse Interstitial Lung Diseases, Pulmonary Arterial Hypertension Primary or Secondary (Post Embolic .....), Cystic Fibrosis of the Adult
- Trial name
- DYSLIM (NCT02229994)
- Testing
- Cross sectional psychometric evaluation of a self-administered dyspnea questionnaire.
- Where
- France
- Volunteers
- 199 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Pulmonary Disease, COPD
The Virtual Reality Therapy as a Pulmonary Rehabilitation Supporting Method
This study evaluates the effectiveness of virtual reality (VR) therapy in the treatment of depression and anxiety symptoms in patients undergoing the pulmonary rehabilitation.
- Conditions
- Pulmonary Disease, COPD, Anxiety State, Stress
- Trial name
- NCT04601545
- Testing
- Pulmonary rehabilitation, Virtual therapeutic support
- Where
- 2 sites in Poland
- Volunteers
- 50 people
- Sponsor
- Wroclaw University of Health and Sport Sciences
COPD, Chronic Obstructive Pulmonary Disease
Study in Patients With COPD
The purpose of this study is to determine which dose of the investigational drug is the most safe and effective for the treatment of COPD compared to the control drug
- Trial name
- NCT00215423
- Testing
- Formoterol Fumarate
- Where
- 7 sites in United States
- Volunteers
- 49 people
- Sponsor
- Dey
COPD
Peak Inspiratory Flow and Dry Powder Inhaler Performance in COPD
The purpose of the study is to determine whether PIF is clinically important when using the Ellipta DPI device. In addition, the study will validate the best/most clinically appropriate way to perform a PIF maneuver, to determine…
- Trial name
- NCT04606394
- Testing
- Trelegy Ellipta 100/62.5/25Mcg Inh 30D, Ventolin 90Mcg/Actuation Inhalation Aerosol
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Pulmonary Research Institute of Southeast Michigan
Asthma, COPD
Factors Influencing on Correctness of Inhalation Technique.
Asthma and COPD are common chronic diseases of respiratory system. The correct use of inhalers is crucial in terms of efficacy of the treatment, however both asthma and COPD patients quite frequently misuse the inhalers.
- Trial name
- NCT04203446
- Testing
- Assessment of correctness of inhaling technique
- Where
- Poland
- Volunteers
- 180 people
- Sponsor
- Medical University of Warsaw
COPD, Chronic Obstructive Pulmonary Disease
Observational Study of the Wellinks Solution Impact on Quality of Life and Clinical Outcomes in Patients With COPD
The clinical objectives of this study are to determine whether utilization of the Wellinks COPD Solution can improve quality of life for patients with COPD, can reduce healthcare resource utilization over time, and can improve…
- Conditions
- COPD, Chronic Obstructive Pulmonary Disease, Chronic Obstructive Pulmonary Disease Severe, Chronic Obstructive Pulmonary Disease Moderate
- Trial name
- ASPIRE (NCT05259280)
- Testing
- Wellinks
- Where
- 2 sites in United States
- Volunteers
- 153 people
- Sponsor
- Convexity Scientific Inc
Chronic Obstructive Pulmonary Disease
The Impact of Early Pulmonary Rehabilitation on Multidimensional Aspect of Dyspnea in COPD Patients After Exacerbation
Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are associated with severe dyspnea and exercise intolerance.
- Trial name
- NCT03611127
- Testing
- pulmonary rehabilitation
- Volunteers
- 80 people
- Sponsor
- Ain Shams University
Pulmonary Disease, Chronic Obstructive
Bone Mineral Density Study In Patients With Chronic Obstructive Pulmonary Disease. DISKUS® Inhaler is a Trademark of the GSK Group of Companies.
This study will last up to 3 years. You will visit the clinic up to 14 times. Certain visits will include lung function tests and scans of your bones.
- Trial name
- NCT00355342
- Testing
- Salmeterol 50 mcg BID, Fluticasone Propionate/Salmeterol 250/50 mcg BID, DISKUS inhaler
- Where
- 37 sites in United States
- Volunteers
- 186 people
- Sponsor
- GlaxoSmithKline
COPD, Healthy
Influence of Trigger Threshold on Controlled Twitch Mouth Pressure
The inspiratory pressure trigger is essential when assessing the twitch mouth pressure (Tw Pmo) for avoiding glottic closure. However, the difference in inspiratory pressure trigger threshold may influence the values of Tw Pmo.
- Trial name
- NCT01891942
- Testing
- twitch by magstim
- Where
- China
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Guangzhou Institute of Respiratory Disease
Pulmonary Disease, Chronic Obstructive
A Study to Assess the Effects of Repeat Doses of Fluticasone Furoate and GW642444M Combination in Healthy Subjects and in Subjects With Severe Impairment.
This study will assess the saftey of giving fluticasone furoate 200mcg/GW642444M 25mcg once daily for 7 days to patients with severe renal imparement.
- Trial name
- NCT01266980
- Testing
- Inhaled FF/ GW642444M (200/25mcg)
- Where
- Czechia
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
OSA, Covid19
COPD Circuit Exercise
This study is being done to understand body's response to hybrid home-based and on-site rehabilitation program utilizing individually tailored exercises throughout a total of 18 sessions with 12 of them occurring onsite, in…
- Conditions
- OSA, Covid19, Residual Symptoms of COVID 19, COPD
- Trial name
- NCT05395390
- Testing
- Exercise (Resistance Training
- Where
- United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Texas A&M University
Pulmonary Disease, Chronic Obstructive
The Impact of a Home-based Pulmonary Telerehabilitation Program in Acute Exacerbations of COPD
COPD impacts a significant proportion of the Veteran population. Acute exacerbations, or flare-ups, of COPD are associated with impaired muscle function and worse quality of life.
- Trial name
- NCT03997513
- Testing
- Pulmonary Telerehabilitation
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- VA Office of Research and Development
Migraine
An Open Label Extension of a Study Comparing Topiramate and Amitriptyline in Migraine Prevention.
The purpose of this study is to assess the long-term safety and effectiveness of topiramate for the prevention of migraine headaches in adults. Topiramate has been approved to prevent migraine headaches in adults.
- Trial name
- NCT00210860
- Testing
- topiramate
- Volunteers
- 142 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Chronic Obstructive Pulmonary Disease (COPD)
A Trial Assessing LAS34273 in Moderate to Severe Stable Chronic Obstructive Pulmonary Disease (COPD)
To evaluate the efficacy and safety of LAS 34273 compared to placebo in patients with moderate to severe COPD during one year of treatment.
- Trial name
- NCT00363896
- Testing
- Aclidinium bromide
- Where
- 132 sites in Andorra, Austria and 14 more
- Volunteers
- 843 people
- Sponsor
- AstraZeneca
Chronic Obstructive Pulmonary Disease, Osteoporosis
Case Control Study: Determinants of Osteoporosis in GOLD II COPD Patients.
Patients with COPD have been found to have an increased risk of osteoporosis. The underlying mechanism is not clear yet. This case control study aims to identify risk factors for osteoporosis in GOLD II COPD patients.
- Trial name
- NCT00725673
- Where
- Netherlands
- Volunteers
- 106 people
- Sponsor
- Catharina Ziekenhuis Eindhoven
Pulmonary Disease, Chronic Obstructive
A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD
The primary purpose of the study is to evaluate the safety and tolerability of fluticasone furoate/GW642444 inhalation powder when administered once-daily for 52 weeks in Japanese patients with COPD.
- Trial name
- NCT01192191
- Testing
- Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg, Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg
- Where
- 35 sites in Japan
- Volunteers
- 187 people
- Sponsor
- GlaxoSmithKline
Chronic Obstructive Pulmonary Disease, Compliance, Patient
AdHerencE to Treatment and quAlity of Life in COPD
The present non-interventional observational study in the Greek population aims at collecting the characteristics of COPD patients selected to be given the inhaled combination of fluticasone propionate and salmeterol in doses of…
- Conditions
- Chronic Obstructive Pulmonary Disease, Compliance, Patient, Quality of Life
- Trial name
- AHEAD (NCT03299673)
- Where
- Greece
- Volunteers
- 600 people
- Sponsor
- Elpen Pharmaceutical Co. Inc.
Pulmonary Disease, Chronic Obstructive
Cross-Over Study in Subjects With COPD, Evaluating Lung Function Response After Treatment With Once Daily Umeclidinium 62.5mcg, Vilanterol 25mcg, and Umeclidinium/Vilanterol 62.5/25mcg
The purpose of this study is to evaluate the lung function response to UMEC/VI, UMEC, and VI in individual patients using a cross-over design. This is a multicenter, randomized, double-blind, 3-way crossover study.
- Trial name
- NCT01716520
- Testing
- Umeclidinium/Vilanterol 62.5/25 mcg, Umeclidinium 62.5 mcg, Vilanterol 25 mcg
- Where
- 21 sites in Estonia, Germany
- Volunteers
- 182 people
- Sponsor
- GlaxoSmithKline
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.